RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.
A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
- Chemical Identification
- Environmental Hazards
- First Aid/Medical Treatment
- Handling/Storage/Shipping/Waste Management
- Personal Protection
- Physical Hazards/Corrective Response Actions
- Physical/Chemical Properties
- Report Abstracts and Studies
- Reproductive Risk
- Toxicology/Health Hazards/Exposure
|Example of Acute Exposure data from MEDITEXT.|
RightAnswer Proprietary Data Sources:
Other Government Links Searched via RegsKnowledge:
State Environmental Regulations
Example Content from MEDITEXT for Pentetate Calcium Trisodium:
Please note: this is an extract of information from a larger document. Full document and details are available by subscription.
ACUTE EXPOSURE INFORMATION
- USES: Pentetate calcium trisodium (Ca-DTPA) is used to treat individuals with known or suspected internal contamination with transuranium ions, specifically plutonium, americium, and/or curium, to increase rates of elimination.
- PHARMACOLOGY: Pentetate calcium trisodium (Ca-DTPA) increases the rates of radiocontaminant elimination by forming stable chelates with metal ions. The calcium ion is exchanged for ions with higher binding capacity. The radioactive chelates are then excreted into the urine by glomerular filtration.
- EPIDEMIOLOGY: Overdose is rare.
- WITH THERAPEUTIC USE
- Chest pain, fever, chills, headache, lightheadedness, dermatitis, pruritus, nausea, vomiting, metallic taste, diarrhea, and Injection site reactions have been reported following therapeutic use of pentetate zinc trisodium (Ca-DTPA). In addition, Ca-DTPA therapy has been associated with trace element deficiency including zinc, magnesium, and manganese depletion. Cough and/or wheezing have been reported in 2 patients who received nebulized Ca-DTPA; one patient had a history of asthma.
- WITH POISONING/EXPOSURE
- Deaths have been reported in patients with severe hemochromatosis who received up to 4 times the recommended daily dose via intramuscular injection.
© 2011-2021 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.